Jiehui Tan

Prof. Dr. Jiehui Tan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KLKai Lei
Kai Lei
YZYutong Zhao
Yutong Zhao
SLShumin Li
Shumin Li
JLJiawei Liu
Jiawei Liu
WCWenhao Chen
Wenhao Chen
JTJiehui Tan
Jiehui Tan
Purpose: Programmed cell death (PCD) mechanisms play crucial roles in cancer progression and treatment response. This study aims to develop a PCD scores prediction model to evaluate the prognosis of hepatocellular carcinoma (HCC) and elucidate the tumor microenvironment differences.Methods: We analyzed transcriptomic data from 363 HCC patients in the TCGA database and 221 patients in the GEO database to develop a PCD prediction model. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics sequencing (ST-seq) data from HCC patients were analyzed to investigate the tumor microenvironment and functional disparities. The oncogenic role of the key gene UBE2E1 in the model was explored in HCC through various in vitro experiments.Results: Seventeen PCD-related genes were identified as significant prognostic indicators, forming the basis of our PCD prediction model. High-PCD scores correlated with poorer overall survival (OS) and exhibited significant predictive capabilities. scRNA-seq analysis revealed distinct tumor cell characteristics and immune microenvironment differences between high- and low-PCD groups. High-PCD tumors showed increased cell proliferation and malignancy-associated gene expression. T cells in high-PCD patients were more likely to be exhausted, with elevated expression of exhaustion markers. ST-seq data also confirmed these results. Among the genes associated with the PCD prognostic model, UBE2E1 was identified as a key oncogenic marker in HCC.Conclusions: The PCD prediction model effectively predicts prognosis in HCC patients and reveals critical insights into the tumor microenvironment and immune cell exhaustion. This study underscores the potential of PCD-related biomarkers in guiding personalized treatment strategies for HCC.

1 May 2025 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
KLKai Lei
Kai Lei
YLYichun Lei
Yichun Lei
ZWZeyao Wang
Zeyao Wang
ZYZhixin Ye
Zhixin Ye
JLJiawei Liu
Jiawei Liu
JTJiehui Tan
Jiehui Tan
Background: The SPP1+ tumor-associated macrophages (TAMs) have been implicated in tumor metastasis and immune evasion. However, the prognostic significance of SPP1+ TAMs in hepatocellular carcinoma (HCC) remains largely unexplored. This study aimed to identify SPP1+ TAMs-related genes and construct a model to predict overall survival (OS) in HCC patients.Methods: Single-cell RNA sequencing (scRNA-seq) datasets from HCC patients were analyzed to identify SPP1+ TAMs. SPP1+ TAMs-related risk score (STRS) was developed using Mendelian randomization (MR) analysis and Least Absolute Shrinkage and Selection Operator (LASSO) regression. HCC patients from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts were stratified into high- and low-STRS groups based on STRS. Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curve analysis, and functional enrichment analysis were performed to assess the prognostic value of STRS.Results: SPP1+ TAMs exhibited strong associations with immunosuppressive functions. 16 SPP1+ TAMs-related genes were used to construct STRS. Patients in the high-STRS group had significantly worse OS than those in the low-STRS group (p < 0.001). ROC analysis demonstrated robust predictive power, with AUC values ranging from 0.685 to 0.748 for 1-year OS, 0.717 to 0.739 for 2-year OS, and 0.719 to 0.738 for 3-year OS. The STRS model also exhibited strong predictive capability for the distinction of drug resistance.Conclusion: This study identified SPP1+ TAMs-related genes as key prognostic indicators in HCC. The STRS model provides an effective tool for predicting patient survival and may facilitate personalized treatment strategies for HCC. These findings enhance the understanding of TAMs-driven immune modulation in HCC and highlight potential therapeutic targets for improving patient outcomes.

30 December 2022 in Gastroenterology Report
Verified
Journal Article
Open access
PDF file
ZCZebin Chen
Zebin Chen
SSShunli Shen
Shunli Shen
WXWenxuan Xie
Wenxuan Xie
JLJunbin Liao
Junbin Liao
SFShiting Feng
Shiting Feng
MKMing Kuang
Ming Kuang
Insufficient post-operative future liver remnant (FLR) limits the feasibility of hepatectomy for patients. Staged hepatectomy is an effective surgical approach that can improve the resection rate of hepatocellular carcinoma (HCC). This study aimed to compare the safety and efficacy of laparoscopic microwave ablation and portal vein ligation for staged hepatectomy (LAPS) and classical associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in the treatment of hepatitis B virus (HBV)-related HCC. Clinical data of patients with HBV-related HCC who underwent LAPS or ALPPS in our institute between January 2017 and May 2022 were retrospectively analysed. A total of 18 patients with HBV-related HCC were retrospectively analysed and divided into the LAPS group (n = 9) and ALPPS group (n = 9). Eight patients in the LAPS group and eight patients in the ALPPS group proceeded to a similar resection rate (88.9% vs 88.9%, P = 1.000). The patients undergoing LAPS had a lower total comprehensive complication index than those undergoing ALPPS but there was not a significant different between the two groups (8.66 vs 35.87, P = 0.054). The hypertrophy rate of FLR induced by ALPPS tended to be more rapid than that induced by LAPS (24.29 vs 13.17 mL/d, P = 0.095). The 2-year recurrence-free survival (RFS) was 0% for ALPPS and 35.7% for LAPS (P = 0.009), whereas the 2-year overall survival for ALPPS and LAPS was 33.3% and 100.0% (P = 0.052), respectively. LAPS tended to induce lower morbidity and FLR hypertrophy more slowly than ALPPS, with a comparable resection rate and better long-term RFS in HBV-related HCC patients.

1 February 2026 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
WCWenhao Chen
Wenhao Chen
JLJiawei Liu
Jiawei Liu
SCShuxian Chen
Shuxian Chen
SLShuyan Li
Shuyan Li
KSKai Shi
Kai Shi
NLNan Lin
Nan Lin
Hepatocellular carcinoma (HCC) is a major cause of cancer deaths. This study developed a clinical prediction model to identify patients likely to respond to transcatheter arterial chemoembolization (TACE) combined with atezolizumab and bevacizumab (Atez/Bev), using Mendelian randomization (MR) to validate the therapeutic effect on HCC via PDCD1, CD274, and VEGFA. A retrospective analysis of 258 unresectable HCC patients administered TACE, with or without Atez/Bev therapy, was conducted. Propensity score matching (PSM) was employed to compare objective response rates (ORRs). A predictive model for response to TACE+Atez/Bev was developed using logistic regression and validated. MR was used to analyze the causal relationships between the PDCD1, CD274, VEGFA genes and Atez/Bev efficacy. After PSM, the TACE+Atez/Bev group demonstrated significantly higher ORR compared with the TACE group (73.8% vs 56.3%, p=0.031). Multivariate logistic regression identified hepatic vein invasion, albumin (ALB), and platelets (PLT) as key outcome factors, which were used to develop a nomogram with AUCs of 0.81 and 0.89 in the training and validation cohorts, respectively. Calibration curve analysis showed good agreement with actual outcomes, and decision curve analysis highlighted the nomogram’s potential for patient selection. MR analyses provided genetic support for the therapeutic target, revealing a significant protective association between PDCD1 inhibition and HCC risk (inverse-variance weighted, DrugOR=0.713, 95% CI: 0.599–0.848, p<0.001). This finding substantiates the biological rationale for the PDCD1 inhibitor atezolizumab. No significant associations were found for CD274 or VEGFA. We developed a predictive model for TACE+Atez/Bev therapy, enabling effective patient screening. MR validated PDCD1’s role in HCC immunotherapy at the genetic level.